NexGenix Pharmaceuticals Holdings Inc., a New York-based developer drugs to treat neurofibromatosis and related sporadic tumors, has raised $3.9 million in Series B funding. No investor information was disclosed. www.nexgenixpharm.com
NexGenix Raises Series B
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.